Le Lézard
Classified in: Health
Subjects: WOM, FDA, DEI

FDA Grants QT Imagingtm Clearance to Calculate Fibroglandular Volume of the Breast


QTscan delivers safe, accurate monitoring of breast cancer treatment

NOVATO, Calif., Sept. 22, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted QT Imaging, Inc. 510(K) clearance to calculate the fibroglandular volume (FGV) of the breast and the ratio of FGV to total breast volume (TGV). This ratio can contribute to an assessment of risk for breast cancer and changes in this ratio can be used to measure the efficacy of medication used to treat or prevent breast cancer.

Unlike traditional breast imaging modalities, the company's QTscantm does not require radiation, injection, or compression, and is highly accurate (+ 0.2%), allowing earlier and more frequent monitoring for women undergoing non-surgical breast cancer treatments such as adjuvant chemotherapy, radiation therapy, cryotherapy, and hormone or selective hormone receptor modulation treatments. No other ultrasound-based breast imaging modality is cleared by the FDA to quantify fibroglandular volume.

"The ability to determine a therapeutic clinical response using a quantitative volumetric method is crucial for effective and timely treatment of breast cancer and for patients at high risk for developing breast cancer who are receiving hormonal therapy. The FGV tool will allow this assessment to be made early and in follow-up to maximize treatment benefit, which is an exciting development for breast care patients," said Dr. Elaine Iuanow, a Breast Imaging specialist and medical consultant for QT Imaging.

"We are excited to expand the tools available using low frequency transmitted ultrasound volography to serve women, especially those with dense breasts, providing an imaging option that is safe, comfortable, and effective," said Dr. John Klock, CEO, Chief Medical Officer and Founder of QT Imaging, Inc.

The proposed indications for use, as designated by the FDA as breakthrough, are:

"The QT Scanner 2000 Model A is for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient's breast. The QT Scanner 2000 Model A software also calculates the breast fibroglandular tissue volume (FGV) value and the ratio of FGV to total breast volume (TBV) value as determined from reflection-mode and transmission-mode ultrasound images of a patient's breast. The device is not intended to be used as a replacement for screening mammography." FDA K220933

About QT Imaging, Inc.

QT Imagingtm is a privately held company engaged in the research, development, and commercialization of an innovative automated imaging system producing high-resolution transmission ultrasound images. The company has received FDA 510(K) clearance for its QT Imaging Breast Scanner. The company's clinical trials have been conducted at prestigious institutions in the US and Europe, and the National Institutes of Health (NIH) has supported the development of the technology with over $15 MM in grants.

The QT Imaging Breast Scanner is indicated for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient's breast. The device is not intended to be used as a replacement for screening mammography.

For more information visit www.qtimaging.com.

Contacts:

Investors
Mikie Price
[email protected]

Media
Michaela Kalff
415.497.1339
[email protected]

SOURCE QT Imaging


These press releases may also interest you

at 08:00
INT'L DAY OF PEOPLE WITH DISABILITIES: Salesian Missions highlights social and educational programs that promote inclusion Almost 1 billion people living with a disability, according to the World Health Organization. Salesian Missions, the U.S....

2 déc 2022
JelloX Biotech is celebrating a robust year of research and product development milestones while showcasing the potential for 3D imaging and AI to be the future of cancer pathology....

2 déc 2022
AUO Display Plus (ADP) will participate in the...

2 déc 2022
Bright Minds Biosciences Inc. ("Bright Minds" or the "Company") is pleased to announce that, further to its news release on November 28, 2022, it has closed a non-brokered private placement of (i) 666,000 pre-funded warrants of...

2 déc 2022
New Capital Enables Growing Specialty Partnership Organization to Continue to Scale Endodontic Practice Partners (EPP), a Nashville-based specialty partnership organization, announces the securing of an additional debt facility to expand its growing...

2 déc 2022
On December 1, 2022, Mr. Wilmot Matthews acquired 5,555,556 units ("Units") of SQI Diagnostics Inc. ("SQI" or the "issuer") at a price of $0.09 per Unit or an aggregate purchase price of $500,000.04 pursuant to the closing of a non-brokered private...



News published on 22 september 2022 at 08:44 and distributed by: